Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Rectal Cancer
•
Medical Oncology
•
Colorectal Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC GI Tumor Board Question
•
Memorial Sloan Kettering
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
Answer from: Medical Oncologist at Community Practice
I would! I did it in a recent patient.
Sign in or Register to read more
20161
Related Questions
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
Is there any circumstance where you would consider bevacizumab in patients with locally advanced colorectal cancer with rectouterine fistula?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
What stroke symptoms would lead you to avoid using oxaliplatin in a patient with metastatic colon cancer and a recent stroke?
Would you ever consider foregoing surveillance CT scans for resected stage II or III colon cancer in favor of circulating ctDNA assays?
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?